Compare Novavax Inc (NVAX) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is far larger — about 2.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| NVAX | VNQI | |
|---|---|---|
Market Cap | $1.82B | $3.80B |
Volume | 6,198,505 | 277,049 |
Sector | Health | — |
52-Week High | $12.56 | $50.76 |
52-Week Low | $6.22 | $41.81 |
Typical Hold Time | 59 Days | 95 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $42.08, up 0.63% with bearish technical signals from moving averages. The ETF provides international real estate exposure across 30+ countries, offering a higher dividend yield than domestic alternatives. Recent news highlights a significant 45.9% drop in short interest in September 2026, while technical indicators show oversold conditions with RSI readings below 30.
The ETF faces headwinds from global real estate market volatility but offers diversification benefits and income potential. Key risks include international currency exposure and regional economic uncertainties. The substantial decline in short interest suggests potential sentiment improvement, though technical trends remain bearish near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
